myMPNteam

When polycythemia vera (PV) progresses to myelofibrosis (MF), which occurs in about 25% of PV patients within 20 years of diagnosis, the bone marrow becomes scarred and cannot produce blood cells properly. This progression requires specific treatment approaches.

Here are the main treatment options:

• Jakafi (ruxolitinib) Show Full Answer

When polycythemia vera (PV) progresses to myelofibrosis (MF), which occurs in about 25% of PV patients within 20 years of diagnosis, the bone marrow becomes scarred and cannot produce blood cells properly. This progression requires specific treatment approaches.

Here are the main treatment options:

• Jakafi (ruxolitinib) - A targeted therapy that helps relieve MF symptoms, typically used for intermediate or high-risk patients
• Inrebic (fedratinib) - Another targeted therapy that can reduce signs and symptoms of MF
• Stem cell transplant - The only potential cure for MF, though it carries serious risks and is usually reserved for younger patients without other health conditions Regular monitoring is essential during treatment. Your healthcare team will need to see you frequently to:

• Check for worsening symptoms
• Monitor for complications like blood clots or bleeding
• Perform regular blood work
• Adjust treatments as needed

Treatment success varies by individual risk factors and disease stage. Working closely with your healthcare team to find the most appropriate treatment approach is crucial.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Primary Myelofibrosis: Causes, Symptoms, and Treatments

How Polycythemia Vera Can Transform Into Myelofibrosis